Published in Drug Alcohol Depend on September 01, 2005
Naltrexone Implants vs. MMT Among Inmates in the Norwegian Correctional Services | NCT00204243
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2006) 3.06
Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health (2013) 1.52
The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol (2008) 1.21
Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend (2007) 1.11
Deficit of circulating stem--progenitor cells in opiate addiction: a pilot study. Subst Abuse Treat Prev Policy (2007) 1.03
Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy (2007) 0.97
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse (2012) 0.95
Addiction: the clinical interface. Br J Pharmacol (2008) 0.94
Preparation and investigation of sustained drug delivery systems using an injectable, thermosensitive, in situ forming hydrogel composed of PLGA-PEG-PLGA. AAPS PharmSciTech (2012) 0.87
Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. Br J Clin Pharmacol (2014) 0.86
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend (2015) 0.82
Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract (2015) 0.81
Advances in opioid antagonist treatment for opioid addiction. Psychiatr Clin North Am (2012) 0.80
Emergency naloxone for heroin overdose: naloxone is not the only opioid antagonist. BMJ (2006) 0.77
Illicit opioid intoxication: diagnosis and treatment. Subst Abuse (2011) 0.77
Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug Alcohol Depend (2014) 0.77
Improved parameters of metabolic glycaemic and immune function and arterial stiffness with naltrexone implant therapy. BMJ Case Rep (2009) 0.75
Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management. Subst Abuse (2012) 0.75
Clinical safety of 1500 mg oral naltrexone overdose. BMJ Case Rep (2010) 0.75
Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health (1999) 7.57
Morbidity associated with non-fatal heroin overdose. Addiction (2002) 2.65
Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med (2002) 2.21
Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol (2004) 2.14
A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust (1999) 2.13
The quantification of mortality resulting from the regular use of illicit opiates. Addiction (1999) 2.10
Overdose among heroin users in Sydney, Australia: II. responses to overdose. Addiction (1996) 1.78
Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction (1998) 1.75
Cognitive impairment among methadone maintenance patients. Addiction (2000) 1.57
Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) (2001) 1.53
Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther (1976) 1.32
A comparison of blood toxicology of heroin-related deaths and current heroin users in Sydney, Australia. Drug Alcohol Depend (1997) 1.08
Heroin-related deaths in Victoria: a review of cases for 1997 and 1998. Drug Alcohol Depend (2001) 1.05
Impact of the heroin 'drought' on patterns of drug use and drug-related harms. Drug Alcohol Rev (2004) 0.98
Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict (1991) 0.97
Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry (1984) 0.90
Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol (2002) 0.89
The treatment of heroin addiction: naltrexone alone and with behavior therapy. Int J Addict (1980) 0.89
A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users. Addict Biol (2003) 0.88
Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug Alcohol Depend (1981) 0.86
The Singapore naltrexone community-based project for heroin addicts compared with drugfree community-based program: the first cohort. J Clin Forensic Med (1996) 0.82
Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev (2002) 0.81
NIDA's naltrexone research program. NIDA Res Monogr (1976) 0.81
Narcotic antagonists. An alternative for treating opioid dependence. Am Pharm (1982) 0.81
The association between hospital overcrowding and mortality among patients admitted via Western Australian emergency departments. Med J Aust (2006) 4.08
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2006) 3.06
Interface between residential aged care facilities and a teaching hospital emergency department in Western Australia. Med J Aust (2006) 2.90
Trauma and tranexamic acid. Med J Aust (2013) 2.73
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain (2013) 2.58
Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain (2013) 1.89
Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend (2012) 1.85
Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab (2010) 1.79
Assessing motivation to quit smoking in people with mental illness: a review. Addiction (2009) 1.73
Five-year outcomes of a brief alcohol intervention for adult in-patients with psychiatric disorders. Addiction (2003) 1.55
Emergency Department diagnosis of pulmonary embolism is associated with significantly reduced mortality: a linked data population study. Emerg Med Australas (2009) 1.54
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) (2007) 1.53
Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology (2007) 1.53
Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain (2007) 1.48
Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl) (2002) 1.47
Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse (2006) 1.44
Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr (2007) 1.44
Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation. Arch Gen Psychiatry (2008) 1.44
Cardiac arrest resuscitation policies and practices: a survey of Australian hospitals. Med J Aust (2003) 1.41
Short-term risk of adverse outcome is significantly higher in patients returning an abnormal troponin result when tested in the emergency department. Emerg Med Australas (2009) 1.38
Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs (2007) 1.37
Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat (2002) 1.36
Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology (2007) 1.26
The Fremantle Primary Prevention Study: a multicentre randomised trial of absolute cardiovascular risk reduction. Br J Gen Pract (2012) 1.19
Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry (2009) 1.18
Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl) (2005) 1.18
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction (2010) 1.16
Treatment of depression in patients with opiate dependence. Biol Psychiatry (2004) 1.16
Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berl) (2006) 1.16
Patient delay and use of ambulance by patients with chest pain. Emerg Med Australas (2005) 1.14
Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology (2013) 1.13
Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend (2007) 1.11
Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction. Biol Psychiatry (2011) 1.10
Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis (2012) 1.08
Sex differences and hormonal influences on response to cold pressor pain in humans. J Pain (2006) 1.08
Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther (2005) 1.06
Measurement invariance in the General Health Questionnaire-12 in young Australian adolescents. Eur Child Adolesc Psychiatry (2004) 1.06
Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology (2013) 1.06
Motivation to quit smoking among hospitalised individuals with and without mental health disorders. Aust N Z J Psychiatry (2010) 1.06
Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) (2010) 1.06
Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry (2012) 1.05
Accuracy of International classification of diseases, 10th revision codes for identifying severe sepsis in patients admitted from the emergency department. Crit Care Resusc (2012) 1.03
Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag (2009) 1.03
Six-month outcomes associated with a brief alcohol intervention for adult in-patients with psychiatric disorders. Drug Alcohol Rev (2002) 1.02
Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology (Berl) (2007) 1.01
A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction (2013) 1.01
The relationship between remoteness and trauma deaths in Western Australia. J Trauma (2009) 1.01
The relationship between opioid and sugar intake: review of evidence and clinical applications. J Opioid Manag (2011) 1.00
Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. J Clin Psychiatry (2010) 0.99
Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain (2012) 0.99
Course of weight change during naltrexone versus methadone maintenance for opioid-dependent patients. J Opioid Manag (2011) 0.98
Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology (2013) 0.97
Use of emergency departments by older people from residential care: a population based study. Age Ageing (2009) 0.96
Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology (Berl) (2010) 0.96
Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav (2009) 0.96
Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med (2013) 0.95
Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement. Drug Alcohol Depend (2012) 0.94
Personal factors influence use of cervical cancer screening services: epidemiological survey and linked administrative data address the limitations of previous research. BMC Health Serv Res (2012) 0.94
A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol (2012) 0.94
A comparison of metropolitan vs rural major trauma in Western Australia. Resuscitation (2011) 0.94
Prescription use disorders in older adults. Am J Addict (2010) 0.93
Modafinil attenuates disruptions in cognitive performance during simulated night-shift work. Neuropsychopharmacology (2005) 0.93
Dextromethorphan and quinidine combination for heroin detoxification. Am J Addict (2008) 0.92
Non-medical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: the need for a more comprehensive approach. Harm Reduct J (2011) 0.92
Cross-national gender differences in the socioeconomic factors associated with smoking in Australia, the United States of America and South Korea. Int J Public Health (2012) 0.92
Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? Drug Alcohol Depend (2013) 0.92
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend (2011) 0.92
Community competence in cardiopulmonary resuscitation. Resuscitation (2002) 0.91
Sex differences and hormonal influences on response to mechanical pressure pain in humans. J Pain (2009) 0.91
A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction (2013) 0.90
Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory. Hum Psychopharmacol (2007) 0.89
Evidence-based paramedic models of care to reduce unnecessary emergency department attendance--feasibility and safety. BMC Emerg Med (2013) 0.89
The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. Neuropsychopharmacology (2010) 0.88
Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteers. Psychopharmacology (Berl) (2009) 0.88
Dementia associated with alcohol and other drug use. Int Psychogeriatr (2005) 0.88
A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users. Addict Biol (2003) 0.88
A pilot study of neurocognitive function in older and younger cocaine abusers and controls. Am J Addict (2011) 0.88
Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics. Prim Care (2011) 0.87
A comparison of major trauma patients transported to trauma centres vs. non-trauma centres in metropolitan Perth. Resuscitation (2011) 0.87
Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend (2012) 0.87
New-onset mania and psychosis following heroin detoxification and naltrexone maintenance. Am J Addict (2005) 0.87
Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats. ACS Chem Neurosci (2017) 0.87
Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biol Psychiatry (2010) 0.86
Prehospital continuous positive airway pressure for acute respiratory failure: a systematic review and meta-analysis. Prehosp Emerg Care (2013) 0.86
The association between naltrexone treatment and symptoms of depression in opioid-dependent patients. Am J Drug Alcohol Abuse (2010) 0.86
A review of human drug self-administration procedures. Behav Pharmacol (2013) 0.85
Major trauma patients transferred from rural and remote Western Australia by the Royal Flying Doctor Service. J Trauma (2011) 0.84
An observational study of bispectral index monitoring for out of hospital cardiac arrest. Resuscitation (2005) 0.84
Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance. J Psychopharmacol (2010) 0.83